Doreen Addrizzo-Harris

Doreen Addrizzo-Harris

Auto-generated profile, based on publicly available information

Doreen Addrizzo-Harris

New York University School of Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Chest
Verified
Journal Article
Closed access
PDF file
Gordon GuyattGordon Guyatt
Gordon Guyatt
DGDavid Gutterman
David Gutterman
MBMichael H. Baumann
Michael H. Baumann
DADoreen Addrizzo-Harris
Doreen Addrizzo-Harris
EHElaine M. Hylek
Elaine M. Hylek
HSHolger Schünemann
Holger Schünemann

1 May 2013 in Chest
Verified
Journal Article
Closed access
PDF file
ABAlessandro Brunelli
Alessandro Brunelli
AKAnthony W. Kim
Anthony W. Kim
KBKenneth I. Berger
Kenneth I. Berger
DADoreen J. Addrizzo-Harris
Doreen J. Addrizzo-Harris

1 May 2013 in Chest
Verified
Journal Article
Closed access
FDFrank C. Detterbeck
Frank C. Detterbeck
SLSandra Zelman Lewis
Sandra Zelman Lewis
RDRebecca Diekemper
Rebecca Diekemper
DADoreen Addrizzo-Harris
Doreen Addrizzo-Harris
WAW. Michael Alberts
W. Michael Alberts

15 December 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
DGDavid E. Griffith
David E. Griffith
GEGina Eagle
Gina Eagle
RTRachel Thomson
Rachel Thomson
TATimothy R. Aksamit
Timothy R. Aksamit
NHNaoki Hasegawa
Naoki Hasegawa
KWKevin L. Winthrop
Kevin L. Winthrop
Rationale: Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex (MAC). Objectives: To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients with refractory MAC lung disease. Methods: Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT were randomly assigned (2:1) to receive ALIS with GBT (ALIS + GBT) or GBT alone. Once-daily ALIS was supplied in single-use vials delivering 590 mg amikacin to the nebulizer. The primary endpoint was culture conversion, defined as three consecutive monthly MAC-negative sputum cultures by Month 6. Measurements and Main Results: Enrolled patients (ALIS + GBT, n = 224; GBT-alone, n = 112) were a mean 64.7 years old and 69.3% female. Most had underlying bronchiectasis (62.5%), chronic obstructive pulmonary disease (14.3%), or both (11.9%). Culture conversion was achieved by 65 of 224 patients (29.0%) with ALIS + GBT and 10 of 112 (8.9%) with GBT alone (odds ratio, 4.22; 95% confidence interval, 2.08–8.57; P < 0.001). Patients in the ALIS + GBT arm versus GBT alone were more likely to achieve conversion (hazard ratio, 3.90; 95% confidence interval, 2.00–7.60). Respiratory adverse events (primarily dysphonia, cough, and dyspnea) were reported in 87.4% of patients receiving ALIS + GBT and 50.0% receiving GBT alone; serious treatment-emergent adverse events occurred in 20.2% and 17.9% of patients, respectively. Conclusions: Addition of ALIS to GBT for treatment-refractory MAC lung disease achieved significantly greater culture conversion by Month 6 than GBT alone, with comparable rates of serious adverse events. Clinical trial registered with www.clinicaltrials.gov (NCT02344004).

15 March 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KOKenneth N. Olivier
Kenneth N. Olivier
DGDavid E. Griffith
David E. Griffith
GEGina Eagle
Gina Eagle
JMJohn P. McGinnis
John P. McGinnis
LMLiza Micioni
Liza Micioni
RWRichard J. Wallace
Richard J. Wallace
Rationale: Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pulmonary nontuberculous mycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. Methods: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. Measurements and Main Results: The modified intention-to-treat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (+20.6 m vs. −25.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. Conclusions: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).

1 February 2000 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
EHEdward M. Harrow
Edward M. Harrow
WAWajdy Abi-Saleh
Wajdy Abi-Saleh
JBJames Blum
James Blum
THTimothy Harkin
Timothy Harkin
SGStefano Gasparini
Stefano Gasparini
AMAtul C. Mehta
Atul C. Mehta
We conducted a prospective multi-institutional clinical study involving community hospitals and academic medical centers to more carefully define the value of computerized tomography (CT) of the chest with transbronchial needle aspiration (TBNA) in the staging of bronchogenic carcinoma (CA), and to assess the predictors of a positive aspirate. Of 360 individuals determined to have bronchogenic carcinoma, 50 of 81 (62%) with small cell carcinoma (SCC) and 135 of 279 (48%) with non-small cell carcinoma (NSCC) had positive aspirates (p = 0.034). TBNA precluded additional thoracic surgery in a total of 104 of 360 (29%) patients and was exclusively diagnostic of carcinoma in 65 of 360 (18%) cases. Right-sided tumors were more likely to have a positive mediastinal TBNA (p = 0.002 to 0.01) as were histologic (67 of 118 [57%]) rather than cytology aspirates (228 of 532 [41%]) (p < 0.001). Sensitivity was > 57% in lymph nodes (LN) ≥ 10 mm, and among LN of equivalent size, right paratracheal and subcarinal sites were most likely to establish malignancy. Preoperative CT is a valuable adjunct in the staging of CA by TBNA. Increasing LN size, right-sided tumors, right paratracheal and subcarinal locations, use of a histology needle, and the presence of SCC are the best predictors of a positive aspirate. Harrow EM, Abi-Saleh W, Blum J, Harkin T, Gasparini S, Addrizzo-Harris DJ, Arroliga AC, Wight G, Mehta AC. The utility of transbronchial needle aspiration in the staging of bronchogenic carcinoma.